CASSANDRA VEALE: Open Payments
NPI 1740996495 · SAINT JOSEPH, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,472 in 74 payments from 14 companies in 2025. Trend: 2023 $1,645 · 2024 $1,857 · 2025 $1,472
Food & beverage: $1,472
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $349 |
| Vanda Pharmaceuticals Inc. | 6 | $201 |
| ABBVIE INC. | 14 | $178 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $165 |
| Alkermes, Inc. | 6 | $138 |
| E.R. Squibb & Sons, L.L.C. | 7 | $115 |
| Janssen Pharmaceuticals, Inc | 6 | $104 |
| Neurocrine BioSciences, Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Lundbeck LLC | 1 | $25 |
Products named: VRAYLAR, FANAPT, CAPLYTA, REXULTI, ARISTADA, ABILIFY MAINTENA, COBENFY, ABILIFY ASIMTUFII.
Industry payments across MO — which companies pay providers there.
